Ken Griffin Viking Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $4.59 Million - $6.49 Million	92,100 Added 9.46%	1,065,500 $67.5 Million
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $15.4 Million - $26.1 Million	-326,000 Reduced 25.09%	973,400 $51.6 Million
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $17.8 Million - $96.6 Million	1,022,600 Added 369.44%	1,299,400 $107 Million
Q4 2023 Feb 14, 2024	SELL	$9.24 - $19.64 $734,580 - $1.56 Million	-79,500 Reduced 22.31%	276,800 $5.15 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $2.73 Million - $4 Million	-250,200 Reduced 41.25%	356,300 $3.94 Million
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $283,444 - $473,489	19,100 Added 3.25%	606,500 $9.83 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $1.01 Million - $2.17 Million	125,500 Added 27.17%	587,400 $9.78 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $1.07 Million - $3.69 Million	392,100 Added 561.75%	461,900 $4.34 Million
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $4,079 - $6,224	-1,600 Reduced 2.24%	69,800 $190,000

473

65.6M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.